Peptide drug leads with increased inhibitory properties synthesized using a divergent strategy

Feb 6, 2018 2:01:22 PM

Protein-protein interactions (PPI) play a major role in regulating many cellular processes, which makes them attractive druggable targets. The large surface area involved in PPIs, however, demands high selectivity of large drug leads such as proteins that can be difficult to modify and fine-tune. To demonstrate a solution to this problem, Christian Tornøe and his colleagues at Novo Nordisk in Denmark have synthesized analogues of Bowman-Birk protease inhibitor (BBI) by using native chemical ligation of peptide hydrazides to link together peptide building blocks to generate several analogues of BBI. This approach required fewer reaction steps than a linear synthesis strategy, and could be used to graft a specific region of a potent trypsin inhibitor onto the α- chymotrypsin-binding loop of BBI that boosted its inhibitory effect four-fold. 

Read More

Topics: Protein-Protein Interactions (PPIs), Prelude peptide synthesizer, Peptide synthesis

Advancing drug targets for peptide-peptide interactions: Peptide flexibility is key in inhibiting the MDM2/p53 interaction

Jun 26, 2017 2:00:00 PM

The search for new drug classes has gone beyond the classically druggable genome, which appears to be limited to around 1,500 proteins. One route is the development of molecules that interfere with the Protein-Protein Interactions (PPIs) that are critical to all cellular processes, such as the regulation of cell growth, DNA replication, transcriptional activation, protein folding, and transmembrane signaling. One PPI-based drug target that involves a well-defined secondary structure is the interaction between the p53 tumor suppressor, the so-called “guardian of the genome” involved in programmed cell death, and MDM2, an important negative regulator of p53. This interaction involves a “hot spot triad” of three residues, Phe19, Trp23 and Leu26, on one face of the α-helical region of p53. Mimicking this region with a peptide became the focus of a collaborative effort between University of Gothenburg, Sweden and St. Jude Children’s Research Hospital in Tennessee, USA and resulted in key insights into the balanced peptide design required to achieve effective PPI inhibition (Danelius et al, 2016).

Read More

Topics: Peptide synthesis, peptide-based PPI inhibitors, PS3 peptide synthesizer, Protein-Protein Interactions (PPIs)